I agree that content from Twitter will be displayed to me.
Postdoc
Claire completed her PhD in 2011 at the Pasteur Institute in Paris, France and worked for two years as a postdoctoral scientist at the Institut de Chimie des Substances Naturelles at Gif-sur-Yvette, France. Since 2013, her research has been focused on the structural characterization of Solute Carrier (SLC) transporters. In humans, there are over 450 SLCs that transport a broad range of substrates, including neurotransmitters, metabolites, and drugs. Thus, SLCs are emerging as important therapeutic targets. First at the mount Sinai School of Medicine in New-York City (2013-2018) and then in Vienna (2018-present), Claire has been working on six distinct SLC families, involved in various diseases and disorders. She uses various computational methods such as homology modeling and molecular docking to explore the structural determinants defining the substrate specificities of SLCs.
Troger F, Delp J, Funke M, van der Stel W, Colas C, Leist M et al. Identification of mitochondrial toxicants by combined in silico and in vitro studies – A structure-based view on the adverse outcome pathway. Computational Toxicology. 2020 May 1;14:100123. doi.org/10.1016/j.comtox.2020.100123
Colas C, Banci G, Martini R, Ecker G. Studies of structural determinants of substrate binding in the Creatine Transporter (CreaT, SLC6A8) using molecular models. Scientific Reports. 2020 Apr 10;10(1). 6241. doi.org/10.1038/s41598-020-63189-z
RESOLUTE consortium. The RESOLUTE consortium: unlocking SLC transporters for drug discovery. Nature Reviews. Drug Discovery. 2020 Apr 7. doi.org/10.1038/d41573-020-00056-6
Hall C, Wolfe H, Wells A, Chien H-C, Colas C, Schlessinger A et al. l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan. Bioorganic & Medicinal Chemistry Letters. 2019 Aug 15;29(16):2254-2258. doi.org/10.1016/j.bmcl.2019.06.033